“LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea

TOKYO and CAMBRIDGE, Mass., May 28, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI” (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD (early AD).LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button